Building a Sustainable Supply Chain for 2030
Niklas Adamsson, Interim CEO and COO, Envirotainer
As 2030 fast approaches, the pharmaceutical sector faces increasing pressure to align with the United Nations Sustainable Development Goals. With climate change now a central global concern, the industry must take decisive action to cut emissions and operate more responsibly - both environmentally and economically.
Pharmaceutical companies must continue to ramp up their environmental commitments, investing over $5.2 billion annually into sustainability programs by 2025, a significant leap from 2020. The supply chain, particularly the logistics and transport systems, are responsible for a significant share of the sector’s carbon footprint.
This transition, however, is anything but simple. Pharmaceutical supply chains are among the most complex and tightly regulated in the world. The challenge now is how to build greener supply chains without compromising on the speed, reliability, or safety of life-saving medications.
Can the pharmaceutical industry innovate fast enough to balance sustainability with operational excellence?
The green challenge
Transport and logistics are among the largest contributors to the environmental impact, adding more layers of complexity due to the need for precise handling, temperature control, and rapid global distribution. As these systems evolve to meet environmental targets, companies must make sure that supply chain efficiency remains uncompromised.
The pharmaceutical industry currently accounts for nearly 5% of global emissions. Most of that comes from Scope 3 emissions, indirect sources like suppliers, transporters, and even end-users, which represent 80–90% of total emissions. While efforts to tackle Scope 1 and 2 emissions have gained traction, reducing Scope 3 impact remains more of a challenge.
Tech-driven solutions
Technology is playing a key role in bridging the gap between sustainability and operational efficiency. Artificial intelligence (AI) can analyze real-time data, from temperature and weather to infrastructure availability, to determine the most efficient transport routes and optimal packaging solutions.
Shipment tracking systems also play a key role in monitoring deliveries in real time, receiving alerts about delays or temperature fluctuations. This enables proactive intervention, ultimately minimizing spoilage and waste.
Beyond transport, designing supply chains that reduce, reuse, and recycle materials can significantly cut Scope 3 emissions. Partnering with suppliers who prioritize sustainability can drive improvements across the supply chain.
Striking the balance
Logistics and packaging decisions are central to the pharmaceutical industry’s ability to reduce emissions without jeopardizing reliability. Every shipment has specific requirements, from temperature sensitivity to route duration, and every touchpoint in the supply chain introduces potential inefficiencies.
Reusable “forever-use” packaging is gaining attention for its longevity and durability. Built from high-performance materials, these containers can endure multiple journeys and extreme conditions, delivering long-term environmental and cost advantages despite their higher upfront cost.
Yet, reusable options aren’t always feasible - particularly in regions with outdated infrastructure or unpredictable logistics. In these cases, single-use packaging remains the most reliable solution. The key is flexibility: companies must choose the right packaging based on each situation, making continuous innovation in packaging materials and designs essential.
The future of the green supply chain
While the pharmaceutical industry has made encouraging progress in reducing its environmental impact, the road to 2030 still requires more. Delivering meaningful reductions in Scope 3 emissions calls for real collaboration across the supply chain.
Encouragingly, the industry is learning that sustainability and performance are not mutually exclusive. Innovations in routing, packaging, and supply chain infrastructure are proving that it's possible to achieve both environmental responsibility and operational efficiency.
The next five years represent a critical window for the sector. Pharmaceutical companies that embed sustainability at the core of their supply chain strategies will not only meet regulatory expectations and global climate targets, but they will build more resilient, agile, and future-ready supply chains. In doing so, they will also contribute to a healthier planet while continuing to deliver life-saving medicines to those who need them most.
Niklas Adamsson, Niklas is the interim CEO and COO at Envirotainer and brings more than 15 years of international leadership experience from various roles. Before joining Envirotainer he held the position as Technical Director Northern Europe at Dassault Systemes. Furthermore, he has also worked within the Operations and Supply Chain domain at Accenture in Sweden. Niklas holds a Ph.D. in engineering from The Royal Institute of Technology in Stockholm and has international academic experience from both ETH in Zurich and the University of Alberta in Canada.
